Combined 3D-quantitative structure–activity relationships and topomer technology-based molecular design of human 4-hydroxyphenylpyruvate dioxygenase inhibitors

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Santucci A, Bernardini G, Braconi D, Petricci E, Manetti F. 4-Hydroxyphenylpyruvate dioxygenase and its inhibition in plants and animals: small molecules as herbicides and agents for the treatment of human inherited diseases. J. Med. Chem. 60(10), 4101–4125 (2017). •• Focuses on the physiological function of HPPD, as well as on nitisinone.
  Medline CASGoogle Scholar
• 2. van Ginkel WG, Gouw ASH, van der Jagt EJ, de Jong KP, Verkade HJ, van Spronsen FJ. Hepatocellular carcinoma in tyrosinemia type 1 without clear increase of AFP. Pediatrics 135(3), e749–e752 (2015).
  MedlineGoogle Scholar
• 3. Kienstra NS, van Reemst HE, van Ginkel WG et al. Daily variation of NTBC and its relation to succinylacetone in tyrosinemia type 1 patients comparing a single dose to two doses a day. J. Inherit. Metab. Dis. 41(2), 181–186 (2018).
  Medline CASGoogle Scholar
• 4. Ndikuryayo F, Kang WM, Wu FX, Yang WC, Yang GF. Hydrophobicity-oriented drug design (HODD) of new human 4-hydroxyphenylpyruvate dioxygenase inhibitors. Eur. J. Med. Chem. 166, 22–31 (2019).
  Medline CASGoogle Scholar
• 5. Moran GR. 4-Hydroxyphenylpyruvate dioxygenase and hydroxymandelate synthase: exemplars of the alpha-keto acid dependent oxygenases. Arch. Biochem. Biophys. 544(SI), 58–68 (2014). •• A synopsis of the literature pertaining to HPPD and hydroxymandelate synthase, which connects those studies that have advanced the understanding of the chemistry of both enzymes.
  Medline CASGoogle Scholar
• 6. VanLith C, Guthman R, Nicolas CT et al. Curative ex vivo hepatocyte-directed gene editing in a mouse model of hereditary tyrosinemia type 1. Hum. Gene Ther. 29(11), 1315–1326 (2018).
  Medline CASGoogle Scholar
• 7. Sundberg J, Wibrand F, Lund AM, Christensen M. Simultaneous quantification of succinylacetone and nitisinone for therapeutic drug monitoring in the treatment of tyrosinemia type 1. J. Chromatogr. B. 1072, 259–266 (2018).
  Medline CASGoogle Scholar
• 8. Markus Grompe MD. The pathophysiology and treatment of hereditary tyrosinemia type 1. Semin. Liver Dis. 21(4), 563–572 (2001).
  MedlineGoogle Scholar
• 9. Fu Y, Sun YN, Yi KH et al. 3D pharmacophore-based virtual screening and docking approaches toward the discovery of novel HPPD inhibitors. Molecules 22(6), 959 (2017).
  Google Scholar
• 10. Bartlett DC, Lloyd C, McKiernan PJ, Newsome PN. Early nitisinone treatment reduces the need for liver transplantation in children with tyrosinaemia type 1 and improves post-transplant renal function. J. Inherit. Metab. Dis. 37(5), 745–752 (2014).
  Medline CASGoogle Scholar
• 11. Larochelle J, Alvarez F, Bussières JF et al. Effect of nitisinone (NTBC) treatment on the clinical course of hepatorenal tyrosinemia in Quebec. Mol. Genet. Metab. 107(1), 49–54 (2012).
  Medline CASGoogle Scholar
• 12. Fu Y, Wang K, Wang P et al. Design synthesis and herbicidal activity evaluation of novel aryl-naphthyl methanone derivatives. Front. Chem. 7, 2 (2019).
  MedlineGoogle Scholar
• 13. Fu Y, Zhang SQ, Liu YX et al. Design synthesis SAR and molecular docking of novel green niacin-triketone HPPD inhibitor. Ind. Crop. Prod. 137, 566–575 (2019).
  CASGoogle Scholar
• 14. Lin HY, Chen X, Chen JN et al. Crystal structure of 4-hydroxyphenylpyruvate dioxygenase in complex with substrate reveals a new starting point for herbicide discovery. Research (Wash. DC) 2019, 2602414 (2019).
  CASGoogle Scholar
• 15. Ellis MK, Whitfield AC, Gowans LA et al. Characterization of the interaction of 2-[2-nitro-4-(trifluoromethyl)benzoyl]-4,4,6,6,-tetramethyl-cyclohexane-135-trione with rat hepatic 4-hydroxyphenylpyruvate dioxygenase. Chem. Res. Toxicol. 9(1), 24–27 (1996).
  Medline CASGoogle Scholar
• 16. Singh D, Kumar J, Kumar A. Isolation of pyomelanin from bacteria and evidences showing its synthesis by 4-hydroxyphenylpyruvate dioxygenase enzyme encoded by hppD gene. Int. J. Biol. Macromol. 119, 864–873 (2018).
  Medline CASGoogle Scholar
• 17. Ellis MK, Whitfield AC, Gowans LA et al. Inhibition of 4-hydroxyphenylpyruvate dioxygenase by 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-13-dione and 2-(2-chloro-4-methanesulfonylbenzoyl)-cyclohexane-13-dione. Toxicol. Appl. Pharmacol. 133(1), 12–19 (1995).
  Medline CASGoogle Scholar
• 18. Ndikuryayo F, Moosavi B, Yang WC, Yang GF. 4-hydroxyphenylpyruvate dioxygenase inhibitors: from chemical biology to agrochemicals. J. Agric. Food Chem. 65(39), 8523–8537 (2017). •• Focuses on the chemical biology of HPPD, discovery of new potential inhibitors and strategies for engineering transgenic crops resistant to current HPPD-inhibiting herbicides.
  Medline CASGoogle Scholar
• 19. Lindstedt S, Holme E, Lock EA, Hjalmarson O, Strandvik B. Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet 340(8823), 813–817 (1992).
  Medline CASGoogle Scholar
• 20. Lin HY, Yang JF, Wang DW et al. Molecular insights into the mechanism of 4-hydroxyphenylpyruvate dioxygenase inhibition: enzyme kinetics x-ray crystallography and computational simulations. FEBS J. 286(5), 975–990 (2019).
  Medline CASGoogle Scholar
• 21. Masurel-Paulet A, Poggi-Bach J, Rolland MO et al. NTBC treatment in tyrosinaemia type I: long-term outcome in French patients. J. Inherit. Metab. Dis. 31(1), 81–87 (2008).
  Medline CASGoogle Scholar
• 22. Garcia MI, de la Parra A, Arias C, Arredondo M, Cabello JF. Long-term cognitive functioning in individuals with tyrosinemia type 1 treated with nitisinone and protein-restricted diet. Mol. Genet. Metab. 11, 12–16 (2017). • A critical investigation that provides that some patients with tyrosinemia type 1. treated with nitisinone and protein-restricted diet are at risk of presenting developmental delay and impaired cognitive functioning.
  CASGoogle Scholar
• 23. Bendadi F, de Koning TJ, Visser G et al. Impaired cognitive functioning in patients with tyrosinemia type I receiving nitisinone. J. Pediatr. 164(2), 398–401 (2014).
  MedlineGoogle Scholar
• 24. de Laet C, Munoz VT, Jaeken J et al. Neuropsychological outcome of NTBC-treated patients with tyrosinaemia type 1. Dev. Med. Child Neurol. 53(10), 962–964 (2011).
  MedlineGoogle Scholar
• 25. Beaudegnies R, Edmunds AJF, Fraser TEM et al. Herbicidal 4-hydroxyphenylpyruvate dioxygenase inhibitors – a review of the triketone chemistry story from a Syngenta perspective. Bioorg. Med. Chem. 17(12), 4134–4152 (2009).
  Medline CASGoogle Scholar
• 26. Li HB, Li L, Li JX, Han TF, He JL, Zhu YQ. Novel HPPD inhibitors: triketone 2H-benzo[b][1,4]oxazin-3(4H)-one analogs. Pest Manag. Sci. 74(3), 579–589 (2018).
  Medline CASGoogle Scholar
• 27. DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. J. Health Econ. 47, 20–33 (2016).
  MedlineGoogle Scholar
• 28. Loza-Mejia MA, Salazar JR, Sanchez-Tejeda JF. In silico studies on compounds derived from Calceolaria: phenylethanoid glycosides as potential multitarget inhibitors for the development of pesticides. Biomolecules 8(4), 121 (2018).
  Google Scholar
• 29. Cruz S, Gomes SE, Borralho PM, Rodrigues CMP, Gaudencio SP, Pereira F. In silico HCT116 human colon cancer cell-based models en route to the discovery of lead-like anticancer drugs. Biomolecules 8(3), 56 (2018).
  Google Scholar
• 30. Nantasenamat C, Prachayasittikul V. Maximizing computational tools for successful drug discovery. Expert Opin. Drug Discov. 10(4), 321–329 (2015).
  Medline CASGoogle Scholar
• 31. Fu Y, Sun YN, Yi KH et al. Combination of virtual screening protocol by in silico toward the discovery of novel 4-hydroxyphenylpyruvate dioxygenase inhibitors. Front. Chem. 6, 14 (2018). • Interesting investigation that provides a virtual screening protocol and novel HPPD inhibitors.
  MedlineGoogle Scholar
• 32. Xu YL, Lin HY, Cao RJ, Ming ZZ, Yang WC, Yang GF. Pyrazolone–quinazolone hybrids: a novel class of human 4-hydroxyphenylpyruvate dioxygenase inhibitors. Bioorg. Med. Chem. 22(19), 5194–5211 (2014).
  Medline CASGoogle Scholar
• 33. Xu YL, Lin HY, Ruan X et al. Synthesis and bioevaluation of pyrazole–benzimidazolone hybrids as novel human 4-hydroxyphenylpyruvate dioxygenase inhibitors. Eur. J. Med. Chem. 92, 427–438 (2015).
  Medline CASGoogle Scholar
• 34. Lewis RW, Botham JW. A review of the mode of toxicity and relevance to humans of the triketone herbicide 2-(4-methylsulfonyl-2-nitrobenzoyl)-13-cyclohexanedione. Crit. Rev. Toxicol. 43(3), 185–199 (2013).
  Medline CASGoogle Scholar
• 35. Fu Y, Liu YX, Yi KH, Li MQ, Li JZ, Ye F. Quantitative structure activity relationship studies and molecular dynamics simulations of 2-(aryloxyacetyl)cyclohexane-13-diones derivatives as 4-hydroxyphenylpyruvate dioxygenase inhibitors. Front. Chem. 7, 556 (2019).
  Medline CASGoogle Scholar
• 36. Fu Y, Liu YX, Kang T, Sun YN, Li JZ, Ye F. Identification of novel inhibitors of p-hydroxyphenylpyruvate dioxygenase using receptor-based virtual screening. J. Taiwan Inst. Chem. Eng. 103, 33–43 (2019).
  CASGoogle Scholar
• 37. Yu SL, Yuan JT, Zhang Y et al. Combined HQSAR topomer CoMFA homology modeling and docking studies on triazole derivatives as SGLT2 inhibitors. Future Med. Chem. 9(9), 847–858 (2017).
  CASGoogle Scholar
• 38. Ye F, Ma P, Zhang YY, Li P, Yang F, Fu Y. Herbicidal activity and molecular docking study of novel ACCase inhibitors. Front. Plant Sci. 9, 1850 (2018).
  MedlineGoogle Scholar
• 39. Ye F, Zhai Y, Kang T et al. Rational design synthesis and structure-activity relationship of novel substituted oxazole isoxazole carboxamides as herbicide safener. Pestic. Biochem. Physiol. 157, 60–68 (2019).
  Medline CASGoogle Scholar
• 40. Fu Y, Zhang D, Kang T, Guo YY, Chen WG, Ye F. Fragment splicing-based design synthesis and safener activity of novel substituted phenyl oxazole derivatives. Bioorg. Med. Chem. Lett. 29(4), 570–576 (2019).
  Medline CASGoogle Scholar
• 41. Wang DW, Lin HY, Cao RJ et al. Synthesis and herbicidal activity of triketone–quinoline hybrids as novel 4-hydroxyphenylpyruvate dioxygenase inhibitors. J. Agric. Food Chem. 63(23), 5587–5596 (2015).
  Medline CASGoogle Scholar
• 42. He B, Dong J, Lin HY et al. Pyrazole-isoindoline-1,3-dione hybrid: a promising scaffold for 4-hydroxyphenylpyruvate dioxygenase inhibitors. J. Agric. Food Chem. 67(39), 10844–10852 (2019).
  Medline CASGoogle Scholar